Pulmonary Arterial Hypertension

About Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension (PAH) is a type of a broader condition known as pulmonary hypertension, which means high blood pressure in the lungs.

PAH is characterized by scarring and narrowing of the small arteries in the lung, which increases pressure and the resistance to blood flow through the lungs.
Preclinical studies have shown that an mTOR inhibitor can reverse or control the disease, including the scarring in the small arteries that are indicated in PAH. [1]

AADi is conducting a phase 1b trial to evaluate the optimal dose and utility use of ABI-009 in the treatment of severe (NCT02587325). Activation of the mTOR pathway has been implicated in the development and progression of PAH and anecdotal clinical data supports the investigation of an mTOR inhibitor to treat PAH [2, 3]. No approved PAH drug addresses ‘proliferative’ component of disease (arterial wall thickening and hyper-proliferaton of smooth muscle and endothelial cells). ABI-009 can achieve high target tissue levels not possible with oral mTOR agents and can be combined with standard therapy in PAH.

You can check out more info about our PAH study and eligibility in our dedicated website here: http://pulmonaryhypertension001.com/

  1. Houssaini et al., Am J Respir Cell Mol Biol 2013 48(5):568-577.
  2. Wessler et al. Chest 2010 138, 991-993.
  3. Seyfarth et al. Pulmonary circulation 2013: 3, 632-638.
  4. AADi, LLC, Data on file


~ 30,000 patients in US (orphan indication)
Only 50% 3 year survival
Current therapies offer only symptomatic relief
No disease modifiers on market
First-in-class opportunity
Can be added to conventional therapy
Opportunity for IV or inhalational route of administration

Pulmonary Arterial Hypertension

March, 7 2019, Aadi Bioscience, Inc. (Aadi), For the first time in his life, Shanahan “Shanny” Dameral, 19, has a girlfriend. Soon, he’ll be graduating with a high school diploma and looking for his first job on the Kitsap Peninsula. What seems routine for many is a big deal for Dameral and other children living with treatment-resistant or intractable epilepsy. For reasons largely unknown, seizures in this subset of children persist long past their discovery in early childhood despite being treated with multiple medications and undergoing surgery to remove the affected parts of their brain. Diagnosed with epilepsy at age 5, life for Dameral has always come with seizures attached. When his seizures returned after a second brain surgery shortly after his 16th birthday, his mom Linley Allen, hoped for a medical breakthrough. “We needed to find something else since another surgery was out of the question,” Allen said. “We had heard about a drug being studied for a more severe seizure condition. I kept holding onto hope that it might be expanded to treat Shanny’s type of seizures because it was all we had at the time.”   See all and the original News article here: New Drug Trial Gives Hope for Treatment-Resistant Epilepsy